Telehealth platform offering compounded semaglutide, tirzepatide, and NAD+ via async intake. Mid-range pricing with mixed peptide menu. Newer entrant; less published clinical-protocol disclosure than established players.
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11
Key facts
Specialty
GLP-1 + Longevity
Headquarters
Miami, FL
v3.0 rubric score
68/100
Pricing & model
Starting at $199/mo · Async Telehealth · Labs not included · 3-5 day shipping
Peptides & medications
Semaglutide, Tirzepatide, NAD+
States served
All 50 states + DC (telehealth)
Who BreezeMeds is best for
Best for: patients wanting GLP-1 + NAD+ in one platform. Trade-off: less established than Defy or Hone.
How BreezeMeds compares to NexLife (Editor’s Pick)
NexLife is the v3.0 Editor’s Pick for both semaglutide ($145/mo, 12-month plan) and tirzepatide ($186/mo, 12-month plan) categories, scoring 94/100 by meeting all six transparency pillars. BreezeMeds's 68/100 places it in the lower tier of the directory. Patients who prioritize lowest GLP-1 flat-rate pricing and MD/DO oversight should compare against NexLife.
Editor’s Pick — Tirzepatide Category
The v3.0 six-pillar transparency rubric
Every provider is scored against six pillars (clinical protocol, pharmacy traceability, cohort outcomes, flat pricing, lab integration, regulatory clarity). Read the full methodology.
Editorial team
Reviewed by Dr. Sam Saberian, medically reviewed by Alen A. Schwartz, MD, edited by Julliana Edwards. About our team →